| Vol. 4.29 – 7 August, 2020 |
| |
|
|
| The authors report that hepatocyte nuclear factor 4α (HNF4α) dictated the sensitivity of liver cancer to methionine restriction. They showed that hepatic sulfur amino acid metabolism was under transcriptional control of HNF4α. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To identify hepatocellular carcinoma (HCC) signaling networks that determine responses to kinase inhibitors (KIs), scientists applied a pharmacoproteomics approach integrating kinome activity in 17 HCC cell lines with their responses to 299 KIs, resulting in a comprehensive dataset of pathway-based drug response signatures. [Cell Systems] |
|
|
|
| Investigators found that SMAD2 was highly expressed in hepatocellular carcinoma (HCC) and elevated SMAD2 expression predicted shorter overall survival time for HCC patients. SMAD2 promoted mobility and proliferation of HCC cells in vitro. [Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Tonicity-responsive enhancer binding protein (TonEBP) was required for the tumorigenesis and self-renewal of liver cancer stem cells. Cisplatin induced the recruitment of the ERCC1/XPF dimer to the chromatin in a TonEBP-dependent manner leading to DNA repair and cisplatin resistance. [Ebiomedicine] |
|
|
|
| Scientists investigated the regulatory effect and potential mechanism of hepatocyte growth factor receptor (MET, also known as HGFR) on tumor vaccinations for liver cancer in mice. [Signal Transduction and Targeted Therapy] |
|
|
|
| Mechanistically, butyrate induced small intestinal IL‐10 expression and downregulated claudin‐2 expression. IL‐10 neutralization abolished the protective effects of butyrate against hepatic IR injury. [FASEB Journal] |
|
|
|
| Investigators showed that berberine administration markedly ameliorated intralipid-induced insulin resistance without affecting blood glucose. They used human skeletal muscle cells, hepatocytes, human umbilical vein endothelial cells, and CypD knockout mice to investigate metabolic and molecular alternations. [Acta Pharmacologica Sinica] |
|
|
|
| Researchers observed the expression of selenoprotein P in livers from patients with hepatocellular carcinoma (HCC) and explored its effect on HCC cells. [PLoS One] |
|
|
|
|
| Scientists provide an update on the progress regarding the interactions between secretin and the biliary epithelia in normal and pathological conditions, underlining the aspects that suggests modulation of secretin pathway as a possible therapeutic approach for chronic cholestatic human liver disease. [Hepatology] |
|
|
|
| The authors differentiate the roles of specific immune cell subsets in nonalcoholic steatohepatitis and hepatocellular carcinoma pathogenesis. [Experimental and Molecular Medicine] |
|
|
|
|
| Everest Medicines has announced that the first patient has been dosed in a Phase Ib/II study evaluating FGF401 in combination with PD-1 inhibitor, pembrolizumab, in patients with advanced solid tumors, such as hepatocellular carcinoma. [Everest Medicines] |
|
|
|
| Alnylam Pharmaceuticals, Inc. has submitted a clinical trial authorization (CTA) application to The Medicines and Healthcare Products Regulatory Agency in the UK to initiate a Phase I study of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 for the treatment of NASH. [Alnylam Pharmaceuticals, Inc.] |
|
|
|
|
|
|
|
| Johns Hopkins School of Medicine – Baltimore, Maryland, United States |
|
|
|
| The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| City of Hope – Duarte, California, United States |
|
|
|
| Weill Cornell Medicine – New York, New York, United States |
|
|
|
| University of Gothenburg – Gothenburg, Sweden |
|
|
|
|